Serum tumor markers in testicular cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 1, 2013, Pages 17-23

  Ehrlich, Yaron ^a   Beck, Stephen D W ^a   Foster, Richard S ^a   Bihrle, Richard ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Prognosis; Serum tumor markers; Testicular neoplasia

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

BINDING AFFINITY; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHORIOCARCINOMA; CROSS REACTION; DISEASE FREE SURVIVAL; FALSE NEGATIVE RESULT; GERM CELL TUMOR; HUMAN; INDUCTION CHEMOTHERAPY; MULTICENTER STUDY (TOPIC); NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEMINOMA; SENSITIVITY AND SPECIFICITY; SMOKING; TESTIS CANCER; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; YOLK SAC TUMOR;

BIOLOGICAL MARKERS; HUMANS; MALE; PROGNOSIS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873999469     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.04.007     Document Type: Review

References (77)

1. International germ cell consensus classification. A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997, 15:594-603. International Germ Cell Cancer Collaborative Group.
2. AJCC (American Joint Committee on Cancer) Cancer Staging Manual 1997, 225. Lippincott-Raven, Philadelphia. 5th ed. I.D. Fleming, J.S. Cooper, D.E. Henson (Eds.).
3. Gitlin D., Boesman M. Serum α-fetoprotein, albumin, and γ-G-globulin in the human conceptus. J Clin Invest 1966, 45:1826-1838.
4. Jacobsen G.K. α-Fetoprotein (AFP) and human chorionic gonadotropin (HCG) in testicular germ cell tumours. A comparison of histologic and serologic occurrence of tumour markers. Acta Pathol Microbiol Immunol Scand A 1983, 91:183-190.
5. Talerman A., Haije W.G., Baggerman L. Serum α-fetoprotein (AFP) in patients with germ cell tumors of the gonads and extragonadal sites: Correlation between endodermal sinus (yolk sac) tumor and raised serum AFP. Cancer 1980, 46:380-385.
6. Bell H. α-Fetoprotein and carcinoembryonic antigen in patients with primary liver carcinoma, metastatic liver disease, and alcoholic liver disease. Scand J Gastroenterol 1982, 17:897-903.
7. Waldmann T.A., McIntire K.R. The use of a radioimmunoassay for α-fetoprotein in the diagnosis of malignancy. Cancer 1974, 34(suppl):1510-1515.
8. Masopust J., Kithier K., Rádl J., et al. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer 1968, 3:364-373.
9. Kitau M.J., Grint P.C., Heath R.B., et al. Serum α-fetoprotein levels in subjects infected with hepatitis B virus. J Med Virol 1988, 26:437-442.
10. Schefer H., Mattmann S., Joss R.A. Hereditary persistence of α-fetoprotein. Case report and review of the literature. Ann Oncol 1998, 9:667-672.
11. Johnson P.J., Poon T.C., Hjelm N.M., et al. Glycan composition of serum α-fetoprotein in patients with hepatocellular carcinoma and nonseminomatous germ cell tumour. Br J Cancer 1999, 81:1188-1195.
12. Mora J., Gascon N., Tabernero J.M., et al. α-Fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. Eur J Cancer 1995, 3:2239-2242.
13. Kawai K., Kojima T., Miyanaga N., et al. Lectin-reactive α-fetoprotein as a marker for testicular tumor activity. Int J Urol 2005, 12:284-289.
14. Mora J., Garrido A., Antonijuan A., et al. Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up. Clin Chem Lab Med 2007, 45:932-933.
15. de Takats P.G., Jones S.R., Penn R., et al. α-Fetoprotein heterogeneity: What is its value in managing patients with germ cell tumours?. Clin Oncol (R Coll Radiol) 1996, 8:323-326.
16. von Eyben F.E. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003, 40:377-427.
17. Vaitukaitis J.L., Braunstein G.D., Ross G.T. A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 1972, 113:751-758.
18. Odell W.D., Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med 1987, 317:1688-1691.
19. Stenman U.H., Alfthan H., Ranta T., et al. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab 1987, 64:730-736.
20. Catalona W.J., Vaitukaitis J.L., Fair W.R. Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: Conversion to negative with testosterone administration. J Urol 1979, 122:126-128.
21. Garnick M.B. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med 1980, 303:1177.
22. Braunstein G.D., Thompson R., Gross S., et al. Marijuana use does not spuriously elevate serum human chorionic gonadotropin levels. Urology 1985, 25:605-606.
23. Markert C.L. Lactate dehydrogenase isozymes: Dissociation and recombination of subunits. Science 1963, 140:1329-1330.
24. Ackers C., Rustin G.J. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage 1 germ cell tumours. Br J Cancer 2006, 94:1231-1232.
25. Venkitaraman R., Johnson B., Huddart R.A., et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 2007, 100:30-32.
26. Weissbach L., Bussar-Maatz R., Mann K. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol 1997, 32:16-22.
27. Huddart R.A., O'Doherty M.J., Padhani A., et al. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage 1 nonseminomatous germ cell tumors: Preliminary report of MRC Trial TE22-the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007, 25:3090-3095.
28. Beck S.D., Foster R.S., Bihrle R., et al. Significance of primary tumor size and pre-orchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell tumors. Urology 2007, 69:557-559.
29. Colls B.M., Harvey V.J., Skelton L., et al. Late results of surveillance of clinical stage 1 nonseminoma germ cell testicular tumours: 17 Years' experience in a national study in New Zealand. BJU Int 1999, 83:76-82.
30. Germà-Lluch J.R., Garcia del Muro X., Maroto P., et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: The experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002, 42:553-562.
31. Read G., Stenning S.P., Cullen M.H., et al. Medical Research Council prospective study of surveillance for stage 1 testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992, 10:1762-1768.
32. Klepp O., Olsson A.M., Henrikson H., et al. Prognostic factors in clinically stage 1 nonseminomatous germ cell tumors of the testis. Multivariate analysis of a prospective multicenter study Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990, 8:509-518.
33. Divrik R.T., Akdogan B., Ozen H., et al. Outcomes of surveillance protocol of clinical stage 1 nonseminomatous germ cell tumors-is shift to risk adapted policy justified?. J Urol 2006, 176:1424-1429.
34. Kollmannsberger C., Moore C., Chi K.N., et al. Non-risk-adapted surveillance for patients with stage 1 nonseminomatous testicular germcell tumors: Diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010, 21:1296-1301.
35. Sturgeon J.F., Jewett M.A., Alison R.E., et al. Surveillance after orchidectomy for patients with clinical stage 1 nonseminomatous testis tumors. J Clin Oncol 1992, 10:564-568.
36. Klepp O., Dahl O., Flodgren P., et al. Risk-adapted treatment of clinical stage 1 nonseminoma testis cancer. Eur J Cancer 1997, 33:1038-1044.
37. Trigo J.M., Tabernero J.M., Paz-Ares L., et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000, 88:162-168.
38. Saxman S.B., Nichols C.R., Foster R.S., et al. The management of patients with clinical stage 1 nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 1996, 155:587-589.
39. Dash A., Carver B.S., Stasi J., et al. The indication for post-chemotherapy lymph node dissection in clinical stage 1s nonseminomatous germ cell tumor. Cancer 2008, 112:800-805.
40. Bosl G.J., Geller N.L., Cirrincione C., et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983, 43:3403-3407.
41. Fossa S.D., Oliver R.T., Stenning S.P., et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997, 33:1380-1387.
42. von Eyben F.E., Madsen E.L., Fritsche H., et al. A new prognostic model for testicular germ cell tumours. APMIS 2003, 111:100-105.
43. Weissbach L., Bussar-Maatz R., Lohrs U., et al. Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study. Seminoma Study Group. Eur Urol 1999, 36:601-608.
44. Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 1989, 7:387-391.
45. Ehrlich Y., Brames J.M., Beck S.D.W., et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a post-chemotherapy retroperitoneal lymph node dissection needed following complete remission?. J Clin Oncol 2010, 28:531-536.
46. de Wit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997, 15:1837-1843.
47. de Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001, 19:1629-1640.
48. Steyerberg E.W., Keizer H.J., Fossa S.D., et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995, 13:1177-1187.
49. Coogan C.L., Foster R.S., Rowland R.G., et al. Post-chemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 1997, 50:957-962.
50. Oldenburg J., Alfsen G.C., Lien H.H., et al. Post-chemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003, 21:3310-3317.
51. Morris M.J., Bosl G.J. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 2000, 163:796-801.
52. Zon R.T., Nichols C., Einhorn L.H. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998, 16:1294-1297.
53. Nichols C.R., Catalano P.J., Crawford E.D., et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998, 16:1287-1293.
54. Beyer J., Kramar A., Mandanas R., et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996, 14:2638-2645.
55. Einhorn L.H., Williams S.D., Chamness A., et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007, 357:340-348.
56. Toner G.C. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: Still not ready for routine clinical use. J Clin Oncol 2004, 22:3842-3845.
57. Vogelzang N.J., Lange P.H., Goldman A., et al. Acute changes of α-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 1982, 42:4855-4861.
58. Fizazi K., Culine S., Kramar A., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004, 22:3868-3876.
59. Gerl A., Clemm C., Lamerz R., et al. Prognostic implications of tumour marker analysis in nonseminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 1993, 29A:961-965.
60. Stevens M.J., Norman A.R., Dearnaley D.P., et al. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995, 13:87-92.
61. Motzer R.J., Mazumdar M., Gulati S.C., et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993, 85:1828-1835.
62. Motzer R.J., Mazumdar M., Bajorin D.F., et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997, 15:2546-2552.
63. Olofsson S., Dahl O., Jerkeman M., et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol 2009, 27:15s.
64. Motzer R.J., Nichols C.J., Margolin K.A., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007, 25:247-256.
65. Baniel J., Foster R.S., Gonin R., et al. Late relapse of testicular cancer. J Clin Oncol 1995, 13:1170-1176.
66. Dieckmann K.P., Albers P., Classen J., et al. Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J Urol 2005, 173:824-829.
67. George D.W., Foster R.S., Hromas R.A., et al. Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 2003, 21:113-122.
68. Gerl A., Clemm C., Schmeller N., et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997, 8:41-47.
69. Ronnen E.A., Kondagunta G.V., Bacik J., et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 2005, 23:6999-7004.
70. Lipphardt M.E., Albers P. Late relapse of testicular cancer. World J Urol 2004, 22:47-54.
71. Ehrlich Y., Baniel J. Late relapse of testis cancer. Urol Clin North Am 2007, 34:253-258.
72. Albers P., Ganz A., Hannig E., et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000, 164:381-384.
73. Wood D.P., Herr H.W., Motzer R.J., et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992, 70:2354-2357.
74. Eastham J.A., Wilson T.G., Russell C., et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994, 43:74-80.
75. Ravi R., Ong J., Oliver R.T., et al. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. Br J Urol 1998, 81:884-888.
76. Beck S.D., Foster R.S., Bihrle R., et al. Outcome analysis for patients with elevated serum tumor markers at post-chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005, 23:6149-6156.
77. van Dijk M.R., Steyerberg E.W., Habbema J.D. Survival of nonseminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006, 42:820-826.